UPDATE: RBC Capital Starts Arrowhead Research (ARWR) at Outperform

(updating comment)

RBC Capital analyst Luca Issi initiates coverage on Arrowhead Research (NASDAQ: ARWR) with a Outperform rating and a price target of $62.00.

The analyst comments "We believe current stock price substantially underappreciates a versatile platform that is de-risked for liver and poised to tackle new tissues. Given 10 clinical assets, 4 targeted tissue and 3 possible pivotal trial starts soon, we think sheer volume of shots on goal is not fully captured by current valuation."

For an analyst ratings summary and ratings history on Arrowhead Research click here. For more ratings news on Arrowhead Research click here.

Shares of Arrowhead Research closed at $36.30 yesterday.

You May Also Be Interested In

• Singular Research Starts Citizens Inc. (CIA) at Buy-Long Term, 'Proven Distribution Growth'
• Arrowhead Pharmaceuticals Inc. (ARWR) Initiates Phase 1/2a Study of ARO-CFB
• DAM Capital Starts Apollo Tyres (APTY:IN) at Buy